H.C. Wainwright raised the firm’s price target on Lenz Therapeutics (LENZ) to $48 from $38 and keeps a Buy rating on the shares. The firm sees positive key opinion leader sentiment for LNZ100, a daily eye drop for presbyopia, heading into the August 8 FDA action date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ: